Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequential Dose-Escalation Randomized Phase 1/2a Study of SNR1611 in ALS
KCT0004911Phase 2Terminated
- Sponsor
- Genuv
- Start
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of trametinib in amyotrophic lateral sclerosis (ALS), sponsored by Genuv. Started Jul 2020; status: terminated.
02
Drugs
trametinib
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on KCT0004911.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0004911.